D-PHARMA
Annual accounts 2025
micro format, filed on 29-01-2026, 91 days before the deadlineTurnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €340,000. Estimated: probably between €240,000 and €640,000.
Balance sheet
balance sheet total €226,463 on 30-09-2025in euro
in euro
Position in the sector
86.1%
Higher than 92% of 25,237 companies in 2025.
7.10
Higher than 91% of 24,245 companies in 2025.
35.4%
Higher than 93% of 24,434 companies in 2025.
Net result: top quarter · Equity: top quarter · Balance sheet total: middle half · Working capital: top quarter
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Balance sheet: assets | ||||
20/58 |
226,463 | 150,012 | 42,800 | |
21/28 |
3,585 | 1,129 | - | |
22/27 |
3,585 | 1,129 | - | |
24 |
3,585 | 1,129 | - | |
29/58 |
222,878 | 148,883 | 42,800 | |
40/41 |
58,636 | 43,516 | 33,211 | |
40 |
52,831 | 43,516 | 33,211 | |
41 |
5,805 | - | - | |
54/58 |
128,032 | 86,321 | 9,585 | |
490/1 |
36,210 | 19,046 | 5 | |
| Balance sheet: equity and liabilities | ||||
10/49 |
226,463 | 150,012 | 42,800 | |
10/15 |
195,050 | 114,838 | 29,095 | |
10/11 |
2,500 | 2,500 | 2,500 | |
14 |
192,550 | 112,338 | 26,595 | |
17/49 |
31,413 | 35,174 | 13,705 | |
42/48 |
31,413 | 32,246 | 13,705 | |
44 |
2,044 | 225 | 1,086 | |
440/4 |
2,044 | 225 | 1,086 | |
45 |
29,369 | 31,782 | 9,829 | |
450/3 |
29,369 | 31,782 | 9,829 | |
47/48 |
- | 240 | 2,790 | |
492/3 |
- | 2,928 | - | |
| Income statement | ||||
9900 |
111,763 | 113,258 | 33,429 | |
630 |
676 | 106 | - | |
640/8 |
1,044 | 245 | 101 | |
9901 |
110,043 | 112,907 | 33,328 | |
65/66B |
8,684 | 3,191 | 33 | |
65 |
8,684 | 3,191 | 33 | |
9903 |
101,358 | 109,717 | 33,295 | |
67/77 |
21,146 | 23,974 | 6,700 | |
9904 |
80,212 | 85,743 | 26,595 | |
9905 |
80,212 | 85,743 | 26,595 | |
| Appropriation of the result | ||||
9906 |
192,550 | 112,338 | 26,595 | |
14P |
112,338 | 26,595 | - | |
| Document | ||||
The notes to these accounts have 5 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 29-01-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankKey figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| 110,718 | 113,013 | - | ||
| 80,888 | 85,848 | - | ||
| 3,132 | 1,234 | - | ||
| 41,711 | 76,736 | - | ||
| 191,465 | 116,637 | 29,095 | ||
| 86.1% | 76.6% | 68.0% | ||
| 7.10 | 4.62 | 3.12 | ||
| 0.16 | 0.31 | 0.47 | ||
| 41.1% | 74.7% | 91.4% | ||
| 35.4% | 57.2% | 62.1% | ||
| 12.75 | 35.42 | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 30-09-2025 | 30-09-2024 | 30-09-2023 |
|---|---|---|---|
| Tangible fixed assets | €3,132 | €1,234 | - |
| €676 | €106 | - |
Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)
Insights on D-PHARMA
The operating result for 2025 is 3% lower than in 2024.
Debt's share of the balance-sheet total falls from 23.4% to 13.9%. Equity is higher and debt is lower.